Contraceptive Drugs - Market Insights, Competitive Landscape, and Market Forecast - 2030

Contraceptive Drugs Market By Product Type (Oral Contraceptive Pills [Combination And Progestin-Only], Injectables, Topical Contraceptives [Gels & Jellies, Patches, And Creams]), By Distribution Channel (Hospitals, Clinics, Retail Pharmacies, Online Pharmacies, And Others), and by geography is expected to grow at an appreciable CAGR forecast till 2030 owing to rising cases of unitended pregnanices across the globe as well as extensive product development activities in contraceptive drugs

Global contraceptive drugs market was valued at USD 8.59 billion in 2023, growing at a CAGR of 4.32% during the forecast period from 2024 to 2030 to reach USD 11.04 billion by 2030. The contraceptive drugs market is witnessing an explosion in product demand due to numerous reasons such as the increasing number of cases of unintended pregnancies among people. Another contributing factor is the rising focus of national and international organizations on popularizing family planning programs and activities across the globe to possibly reduce population burden in coming years. Additionally, product development activities in terms of non-hormonal products such as the Phexxi gel, product approvals, and regulatory support such as assigning of special designations also play a key role in establishing an upward growth trend in the contraceptive drugs market during the forecast period from 2024 to 2030.

Contraceptive Drugs Market Dynamics:

One of primary factor driving the contraceptives market growth is the upsurge in cases of unintended pregnancies across the globe, which is expected to influence the demand for contraceptive drugs. For instance, as per the data provided by the World Health Organization (2023), 4 million women living in low and middle-income countries have unintended pregnancies annually across the globe. This leads to 25 million unsafe abortions and 47,000 maternal deaths every year globally. Modern methods of contraception have a vital role in preventing unintended pregnancies. The United Nation's Department of Economic and Social Affairs 2019 statistics mentioned that approximately 922 million women of reproductive age (or their partners) use contraception methods comprising various products of which contraceptive pills are one of the most common and reliable sources for avoiding unintended pregnancies. Moreover, as per numbers revealed by the United Nations, in 2022, over 1.4 billion unintended pregnancies happened as an impact of the COVID-19 pandemic which resulted in global disruption of the supply chain of contraceptives including contraceptive drugs. This primarily affected developing nations as majority of the population receive their contraceptive drugs from government-run centers. The impact of the disruption of the supply chain of contraceptive drugs and direct surge in unintended pregnancies across the globe majorly in emerging economies further helped lay emphasis on the growing need for contraceptive drugs across the globe, thereby providing a positive growth outlook for the contraceptive drugs market during the forecast period.

Another prominent factor responsible for the increasing demand of contraceptive drugs is the growing focus of governments as well as international organizations in popularizing population control is expected to drive the demand for contraceptives during the forecast period. For instance, keeping in line with the sustainable development goals for 2030 (SDG 2030) put forth by the United Nations, the Family Planning 2030 program aims at achieving voluntary modern contraceptive use by anyone who wants it by investing in adolescents and youth, strengthening supply chains so that contraceptive drugs reach those who need them, ensuring that family planning services and supplies have sustained funding support, and improving the quality of care in family planning service. The United Nations Population Fund which is a global partnership among alliance of governments, foundations, multilateral agencies, civil society and youth organizations, and private sector partners that are collaborating to advance rights-based family planning have committed a collected fund of USD 3.1 billion toward widening access to family planning over the next five years. Similarly, efforts are also being made by several governments at national level in order to advocate planned parenthood and decrease incidents of maternal mortality. For example, the Indian government initiated a slew of measures to sensitize people and create awareness regarding population control by launching programs such as Mission Parivar Vikas (launched in 2016) which aims to reduce the total fertility rate to 2.1 by the year 2025 in 7 high populated states of the country. Other measures include clinical outreach teams (COT) scheme and compensation scheme for sterilization acceptors among others. Therefore, the growing emphasis on planned parenthood in order to avoid unintended pregnancies and outcomes associated with it such as financial burden, risk to maternal and fetal health are prompting governments and organizations working in the domain to popularize the need for contraception leading to an overall increase in the contraceptive drugs market growth.

However, side-effects associated with contraceptive drugs and no protection against sexually transmitted diseases may prove to be deterrents to contraceptive drugs market growth.

Besides the above-mentioned factors, the contraceptive drugs market was impacted by the imposition of the lockdown due to the COVID-19 pandemic. Even though this specific market maintained a high product demand during the COVID-19 pandemic, there was a significant disruption in supply chain wherein products such as contraceptive pills, creams, and gels failed to reach government-run distribution centers primarily in developing countries. Although, the post-pandemic scenario provides an opportune environment for revenue generation for the contraceptive drugs market due to the resumption of activities in full capacity helping in the restoration of supply chain thereby improving the market outlook for the contraceptive drugs market during the forecast period (2024-2030).

Contraceptive Drugs Market Segment Analysis:

Contraceptive Drugs Market by Product Type (Oral Contraceptive Pills [Combination and Progestin-Only], Injectables, Topical Contraceptives [Gels & Jellies, Patches, and Creams]), by Distribution Channel (Hospitals, Clinics, Retail Pharmacies, Online Pharmacies, and Others), and by Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the product type segment of the contraceptive drugs market, oral contraceptive pills is estimated to account for significant revenue share in the year 2023. Between the two, the combined oral contraceptive pills were more popular in 2022. This can be ascribed to the advantages associated with the combined oral contraceptive pills. These pills have proven to be 99% effective when taken correctly following the recommended regimen. Besides helping in providing contraceptive benefits, combined contraceptive pills offer other benefits such as helping with the premenstrual syndrome, heavy periods, acne, among other indications. Considering the advantages associated with the combined oral contraceptive pills, there has been a growing interest in product launches for the same, for instance, in April 2022, Mayne Pharma received the regulatory approval from the US Food and Drug Administration (FDA) for their combined oral contraceptive- NEXTSTELLIS (3 mg drospirenone [DRSP] and 14.2 mg estetrol [E4] tablets). Therefore, the market for combined oral contraceptive pills is predicted to register remarkable growth during the forecast period eventually driving the growth of contraceptive drugs market in coming years.

North America is expected to dominate the overall Contraceptive Drugs Market:

Among all the regions, North America is projected to amass the largest share in revenue generation in the contraceptive drugs market. Some of the factors responsible for the growth of the North America contraceptive drugs market is the rising incidence of unintended pregnancies in the region, rise in focus towards family planning and prevention of unintended pregnancy, growing use of contraceptive drugs amongst females for, and rising awareness pertaining to modern contraception methods.

One of the prominent markets in the North American region is the United States. An increase in unintended pregnancies is one the key factors leading to the growing need for contraceptive drugs, thereby causing an increase in the overall growth of contraceptive drugs market. For instance, as per the Office of Disease Prevention and Health Promotion (2023), in 2020, almost half (45%) of the 6.1 million annual pregnancies in the United States were found to be unintended. In addition, the rising number of medication abortions also present a scenario for the demand for contraceptive drugs. For instance, as per the Guttmacher Institute, in 2020, medical abortions accounted for the largest share in all of US abortions. This could further be attributed to the disruption of the supply chain due to the COVID-19 pandemic which affected the production as well as the distribution of the contraceptive drugs across the country. In addition to the facts stated above, the extensive research and development activities focused on developing male as well as non-hormonal contraceptive drugs is another factor that may contribute in the growth of the United States contraceptive drugs market. For example, one such product in development is the contraceptive gel intended to be used by men which is in clinical trials in the United States, among other countries. The gel formulation was developed by the Population Council and NIH's Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). The gel contains segesterone acetate, a synthetic progestin, which blocks natural testosterone production in the testes and reduces sperm production. Therefore, such initiatives and product development activities are expected to pave the way for new products to reach the market, thereby providing a prosperous growth environment for the contraceptive drugs market growth in the coming years in the United States as well as in the North America region.

Contraceptive Drugs Market Key Players:

Some of the key market players operating in the contraceptive drugs market includes Abbvie Inc, BAYER AG, Viatris Inc, Gedeon Richter Plc., Agile Therapeutics, Evofem Biosciences, Inc., Amneal Pharmaceuticals LLC., Pfizer Inc, Hana, Maxwellia Ltd., Piramal Enterprises, Mankind Pharma, HLL Lifecare Limited, Theramex, Besins Healthcare, Marlborough Pharmaceuticals, Teva Pharmaceuticals USA, Inc, and others.

Recent Developmental Activities in Contraceptive Drugs Market:

In May 2020, the US Food and Drug Administration approved Phexxi(TM) (lactic acid, citric acid and potassium bitartrate) vaginal gel for the prevention of pregnancy in females with reproductive potential.

In January 2020, Bayer and Dare Bioscience entered into an exclusive license agreement for the US commercial rights to investigational hormone-free, monthly contraceptive Ovaprene®. As per this agreement, Bayer may commercialize Dare's investigational contraceptive product, Ovaprene® in the United States once approved by the FDA.

In December 2020, Gedeon Richter Plc. signed an asset purchase agreement with Janssen Pharmaceutica NV in respect of Janssen's Outside US Evra® transdermal contraceptive patch assets. The transaction amounted to approximately around USD 263.5 million.

Key Takeaways from the Contraceptive Drugs Market Report Study

• Market size analysis for current contraceptive drugs market size (2023), and market forecast for 5 years (2024-2030)
• The effect of the COVID-19 pandemic on this market is significant. To capture and analyze suitable indicators, our experts are closely watching the contraceptive drugs market.
• Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for last 3 years
• Key companies dominating the global contraceptive drugs market.
• Various opportunities available for the other competitors in the contraceptive drugs market space.
• What are the top performing segments in 2023? How these segments will perform in 2030.
• Which is the top-performing regions and countries in the current contraceptive drugs market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for contraceptive drugs market growth in the coming future?

Target Audience who can be benefited from this Contraceptive Drugs Market Report Study

• Contraceptive drugs products providers
• Research organizations and consulting companies
• Contraceptive drugs-related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and traders dealing in contraceptive drugs
• Various end users who want to know more about the contraceptive drugs market and latest technological developments in the contraceptive drugs market.

Frequently Asked Questions for Contraceptive Drugs Market:

1. What are Contraceptive Drugs?

Contraceptive drugs are medication with the primary action to avoid conception by preventing the fusion of the gametes by employing different techniques such as the inhibition of follicular development, ovulation which is followed majorly in oral contraceptive pills, as well as the making the environment hostile for the sperms to survive as followed by spermicidal products.

2. What is the market for Global Contraceptive Drugs?

Global contraceptive drugs market was valued at USD 8.59 billion in 2023, growing at a CAGR of 4.32% during the forecast period from 2024 to 2030 to reach USD 11.04 billion by 2030.

3. What are the drivers for Global Contraceptive Drugs Market?

The contraceptive drugs market is witnessing an explosion in product demand due to numerous reasons such as the increasing number of cases of unintended pregnancies among people. Another contributing factor is the rising focus of national and international organizations on popularizing family planning programs and activities across the globe to possibly reduce population burden in coming years. Additionally, product development activities in terms of non-hormonal products such as the Phexxi gel, product approvals, regulatory support such as assigning of special designations also play a key role in establishing an upward growth trend in the contraceptive drugs market during the forecast period from 2024-2030.

4. Who are the key players operating in Global Contraceptive Drugs Market?

Some of the key market players operating in the contraceptive drugs market includes Abbvie Inc, BAYER AG, Viatris Inc, Gedeon Richter Plc., Agile Therapeutics, Evofem Biosciences, Inc., Amneal Pharmaceuticals LLC., Pfizer Inc, Hana, Maxwellia Ltd., Piramal Enterprises, Mankind Pharma, HLL Lifecare Limited, Theramex, Besins Healthcare, Marlborough Pharmaceuticals, Teva Pharmaceuticals USA, Inc, and others.

5. Which region has the highest share in Contraceptive Drugs market?

Among all the regions, North America is projected to amass the largest share in revenue generation in the contraceptive drugs market. Some of the factors responsible for the growth of the North America contraceptive drugs market is the rising incidence of unintended pregnancies in the region, rise in focus towards family planning and prevention of unintended pregnancy, and rising awareness pertaining to modern contraception methods.